Drug Availability

There has been concern about drug shortages during the COVID-19 pandemic. The CLL Society investigated these concerns and has been reassured that, at least for ibrutinib, there will be no impacts to the product supply.

ASH 2020 Update: Anti-SARS-CoV-2 Antibody Response in Patients with Chronic Lymphocytic Leukemia
January 4, 2021

NCCN Recommends Zanubrutinib as First-Line, Second-Line Therapy in CLL/SLL
January 4, 2021

Update on CALAVI Phase II trials for Acalabrutinib in Patients Hospitalized with Respiratory Symptoms of COVID-19
January 4, 2021

CLL Society’s Official Statement Concerning SARS-CoV-2 Vaccine in CLL Patients 1/04/2021
January 4, 2021

Stop the spread of COVID-19!
December 20, 2020

Do I need a Pulse Oximeter?
December 4, 2020